Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
AUTHORIZED USE IN THE U.S.
INDICATION (U.S.)
SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer SPIKEVAX to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of SPIKEVAX.
Warnings and Precautions
Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of SPIKEVAX.Myocarditis and Pericarditis: Post marketing data demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. The observed risk is highest in males 18 years through 24 years of age.Syncope (fainting): May occur in association with administration of injectable vaccines, including SPIKEVAX. Procedures should be in place to avoid injury from fainting.Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to SPIKEVAX.Limitations of Vaccine Effectiveness: SPIKEVAX may not protect all vaccine recipients.
Adverse Reactions
The most commonly reported (≥10%) adverse reactions following any dose in any indicated patient population were pain at the injection site, headache, fatigue, myalgia, chills, arthralgia, axillary swelling/tenderness, nausea/vomiting, swelling at the injection site, erythema at the injection site, and fever.
Reporting Adverse Events and Vaccine Administration Errors
The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
Please see the SPIKEVAX Full Prescribing Information.
Please see the Moderna COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine for more information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's regulatory submission to the U.S. FDA for its Spikevax 2025-2026 formula, including the potential for approval in the U.S. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:Chris RidleyGlobal Head of Media Relations+1 617-800-3651Chris.Ridley@modernatx.com
Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Erie County mosquitoes test positive for West Nile Virus
(WJET/WFXP)– Erie County has confirmed the first group of mosquitoes to test positive for West Nile Virus this year. The sample was collected in Harborcreek Township on May 28, with additional monitoring conducted in the area where the samples were collected, along with control work based on the number and types of mosquitoes that tested positive. See an increase in bugs? Here's what they are Certain mosquito species carry West Nile virus and can cause an infection in humans that can inflame the brain, and can affect any age group of people, though older adults and those with compromised immune systems have the highest risk of developing severe illness. To reduce the number of mosquitoes around homes and neighborhoods, the Erie County Department of Health recommends getting rid of standing water, where mosquitoes lay their eggs, and following the following tips: Dispose of any refuse that can hold water, such as tin cans, containers, and, in particular, used tires. Tires have become the most important mosquito breeding site in the country. Drill holes in the bottoms of recycling containers, and check uncovered junk piles. Clean clogged roof gutters every year, and check storm drains, leaky faucets, and window wells. Empty accumulated water from wheelbarrows, boats, cargo trailers, toys, and ceramic pots. If possible, turn them over when not using them. Do not allow water to stagnate in birdbaths, ornamental pools, water gardens, and swimming pools or their covers. Ornamental pools can be aerated or stocked with fish. Swimming pools should be cleaned and chlorinated when not in use. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Washington Post
33 minutes ago
- Washington Post
Measles vaccination rates drop after COVID-19 pandemic in counties across the US
Childhood vaccination rates against measles fell in the years after the COVID-19 pandemic in nearly 80% of the more than 2,000 U.S. counties with available data — including in states that are battling outbreaks this year. A Johns Hopkins University study, published in JAMA this week , illustrates where more vulnerable communities are located. The results mirror trends established at state and national levels : Routine childhood vaccination rates are dropping.
CBS News
33 minutes ago
- CBS News
Air quality alert issued in Philadelphia, doctors urge high risk groups to limit outdoor activity
Doctors urge high risk groups to limit outdoor activity after a Code Orange was issued in Philly Doctors urge high risk groups to limit outdoor activity after a Code Orange was issued in Philly Doctors urge high risk groups to limit outdoor activity after a Code Orange was issued in Philly A Code Orange alert is in effect in Philadelphia, meaning the air is potentially unhealthy for sensitive groups. Tuesday's warm muggy weather may seem like a normal day, but doctors say people with medical conditions, the elderly and young children should be extra careful outside. "Not being able to catch your breath or control your breathing is a very scary experience," said Joy Ezekiel, a lung patient. Ezekiel, who lives in South Jersey, has lung damage from long COVID. She says even a beautiful warm day can make it difficult to breathe. "The days look beautiful. The sun is shining, but it feels like you're being suffocated," Ezekiel said. She relies on a rescue inhaler to help her breathe on bad air days. "Breathing hot humid air, especially humid air, it's like breathing water and it's much harder to move that air in and out of lungs even for healthy people," said Dr. Emilio Mazza of Virtua Our Lady of Lourdes Hospital. CBS Philadelphia Mazza says people can get into trouble if they ignore breathing difficulties when there's an air alert. "We do see a lot more patients coming in the emergency room," Mazza said. He says the haze hanging over the Philadelphia region can be dangerous for people in high-risk groups. Ozone from the heat mixing with pollution and elevated smoke from Canadian wildfires impacts the lungs. "It triggers a whole response that causes inflammation that causes the airways to swell and with smaller airways it's harder to breathe," Mazza said. He recommends sensitive groups to stay inside in air conditioning as much as possible. That means some may have to avoid the pretty sunsets until the air clears up so everyone can enjoy the scenery. Doctors say people concerned about the air alert should avoid being outside in the late afternoon, when ozone levels tend to be more elevated.
